Back to Peptides
sexual_healthMedium Risk

PT-141

Also known as: Bremelanotide, Vyleesi

Half-life:
2–3 hours

Administration Routes

subcutaneousintranasal
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a melanocortin receptor agonist researched for its effects on sexual function in both men and women. It acts centrally via the hypothalamus rather than through vascular mechanisms, distinguishing it from PDE5 inhibitors. It received FDA approval as Vyleesi for HSDD in premenopausal women and is also used off-label in compounded form. Common side effects include transient nausea and flushing.

Primary Research Areas

  • sexual_health

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Providers Offering PT-141